Lilly’s LOXO-292 shrinks tumours in lung cancer trial
pharmafile | September 9, 2019 | News story | Research and Development, Sales and Marketing | Cancer, Eli Lilly, lung cancer, pharma
Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung cancer patients.
LOXO-292 (selpercatinib) treatment resulted in a 68% objective response in patients who had been previously heavily pre-treated with at least 48% of those having received at least one multikinase inhibitor. Additionally in 11 patients whose cancer had spread to the brain, 91% saw tumour shrinkage by 30% or more.
LOXO-292 is intended for patients with rare RET abnormalities occurring in 2% of non-small cell lung cancers (NSCLC) patients as well as 10-20% of papillary thyroid cancers and around 60% of medullary thyroid cancers.
Dr Alexander Drilon, lead investigator at the Memorial Sloan Kettering Cancer Center in New York, said: “We are encouraged by these data as there is currently an unmet need to provide genomically-tailored therapy to patients with RET fusion-positive NSCLCs.
“We look forward to submitting the NDA later this year, and should selpercatinib receive regulatory approval, patients with RET fusion-positive NSCLC will finally have their first genomically guided medicine.”
Safety analyses showed that, out of 531 patients, only nine dropped out due to side-effects. The most commonly reported side-effects were diarrhoea, dry mouth, increased liver enzymes, fatigue, high-blood pressure and headache.
Other investigations into highly selective RET inhibitors include RXDX-105 and BLU-667, the latter of which is set to be filed for FDA approval by its owner Blueprint Medicines in the first quarter of 2020.
Nikhil Kiran
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …
